IFN-α has been used therapeutically against hepatitis C, and more recently IFN-α was shown to protect against pulmonary tissue damage from the highly pathogenic avian influenza virus, H5N1 [49]. The gene discussed is IFNA17; the disease is hepatitis C virus infection.